Generalized Anxiety Disorder Market

Market Overview:

The 7 major generalized anxiety disorder markets reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.4 Billion by 2034, exhibiting a growth rate (CAGR) of 5.85% during 2024-2034.

The generalized anxiety disorder market has been comprehensively analyzed in IMARC's new report titled "Generalized Anxiety Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Generalized anxiety disorder (GAD) refers to a mental health condition characterized by excessive and persistent worry or anxiety about various aspects of life. People suffering from the ailment often experience chronic and unrealistic concerns about everyday things, such as work, health, family, finances, etc., even when there is no apparent reason for the stress. This anxiety is typically difficult to control and may interfere with daily functioning and quality of life. The common symptoms of the illness include restlessness, fatigue, muscle tension, irritability, difficulty sleeping or concentrating, overthinking, indecisiveness, a constant feeling of tension, sweating, gastrointestinal problems, trembling, shortness of breath, etc. Diagnosing GAD typically involves a combination of clinical evaluation, medical history, and psychological testing. The diagnostic guidelines outlined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) are used to evaluate the presence and severity of disease symptoms. Additionally, several standardized questionnaires, such as the Generalized Anxiety Disorder 7-item scale (GAD-7) or the Penn State Worry Questionnaire (PSWQ), are recommended to rule out any medical conditions that could contribute to the underlying indications.

The increasing cases of imbalances or irregularities in certain neurotransmitters, like serotonin, norepinephrine, dopamine, etc., are primarily driving the generalized anxiety disorder market. In addition to this, the rising incidences of various associated risk factors, such as chronic exposure to stressful situations, trauma, genetic predisposition, abuse, significant life changes, etc., are also creating a positive outlook for the market. Moreover, the escalating adoption of effective medications, including benzodiazepines and selective serotonin reuptake inhibitors (SSRIs), to ease the symptoms of the illness is further bolstering the market growth. Apart from this, the emerging popularity of cognitive behavioral therapy, which helps in identifying and challenging negative or unhealthy thought patterns and replacing them with more realistic and positive ones, is also acting as another significant growth-inducing factor. Furthermore, the escalating application of mindfulness-based stress reduction techniques to treat this condition on account of their several benefits, like reduced anxiety symptoms, enhanced emotional regulation skills, increased resilience, improved overall well-being, etc., is expected to drive the generalized anxiety disorder market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the generalized anxiety disorder market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for generalized anxiety disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the generalized anxiety disorder market in any manner.

Recent Developments:

• In March 2024, Mind Medicine (MindMed) Inc. reported that the FDA had granted breakthrough status to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder. The company also reported that its Phase 2b research of MM120 in generalized anxiety disorder fulfilled its key secondary target, and 12-week topline data showed clinically and statistically substantial durability of action through Week 12.

Key Highlights:

• Generalized anxiety disorder is a moderately common disorder, affecting approximately 3.1% of the U.S. population.
• The frequency of generalized anxiety disorder in children and adolescents varies from 2.9% to 4.6%.
• An estimated 5.7% of adults in the United States experience generalized anxiety disorder at some point in their lives.
• Generalized anxiety disorder typically develops in adulthood, with about 5% of cases starting before the age of 13.
• Generalized anxiety disorder is more common in women than males, and in middle-aged and older persons.

Drugs:

Lexapro (Escitalopram) is an antidepressant medicine used to treat generalized anxiety disorder in adults and children patients aged 7 years and older. The recommended starting dose of Lexapro for adults is 10 mg once a day, while the recommended starting dose for pediatric patients aged 7 years and above is 10 mg once daily.

SEP-363856, a TAAR1 agonist with 5-HT1A agonist action, is presently under investigation for the management of major depressive disorder and generalized anxiety disorder, with other indications under consideration. The medicine is being developed and commercialized in partnership by Otsuka Pharmaceutical Co., Ltd, Sunovion, and Sumitomo Pharma Co., Ltd.

ABBV-932 is under clinical development by AbbVie for the treatment of generalized anxiety disorder. The treatment candidate is a DRD2 and DRD3 dopamine receptor modulator that is delivered orally in the form of capsules.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the generalized anxiety disorder market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the generalized anxiety disorder market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current generalized anxiety disorder marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the generalized anxiety disorder market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the generalized anxiety disorder market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the generalized anxiety disorder market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of generalized anxiety disorder across the seven major markets?
• What is the number of prevalent cases (2018-2034) of generalized anxiety disorder by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of generalized anxiety disorder by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with generalized anxiety disorder across the seven major markets?
• What is the size of the generalized anxiety disorder patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of generalized anxiety disorder?
• What will be the growth rate of patients across the seven major markets?
   

Generalized Anxiety Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for generalized anxiety disorder drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the generalized anxiety disorder market?
• What are the key regulatory events related to the generalized anxiety disorder market?
• What is the structure of clinical trial landscape by status related to the generalized anxiety disorder market?
• What is the structure of clinical trial landscape by phase related to the generalized anxiety disorder market?
• What is the structure of clinical trial landscape by route of administration related to the generalized anxiety disorder market?